WHAT WE DO
ENDOTIS PHARMA is a leader in the development of small glyco-drugs. The company has built a breakthrough thrombosis portfolio, a unique hemato-oncology pipeline and a powerful discovery engine that provides transformational R&D capabilities.
R&D programs Our science Targeted diseasesNews
13.07.2010
Parc Biocitech, Paris (France), le 8 ...
03.06.2010
Biocitech Park, Paris (France), June ...
29.04.2010
Biocitech Park, Paris (France), April 30...
29.04.2010
Biocitech Park, Paris, France, le 30 ...
Latest News
Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant EP217609 at the 21st International Congress on ThrombosisBiocitech Park, Paris (France), July 8th, 2010 - Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications...
Latest Publications
Endotis Pharma presents Phase I clinical trial resultsfor a first-in-class synthetic parenteral neutralizable anticoagulant EP217609at the 21st International Congress on ThrombosisBiocitech Park, Paris (France), July 8th, 2010 - Endotis Pharma, the biopharmaceutical company dedicated to the discovery and development of small-glyco drugs for applications i...